Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

Myron S. Czuczman*, Aron Thall, Thomas E. Witzig, Julie M. Vose, Anas Younes, Christos Emmanouilides, Thomas P. Miller, Joseph O. Moore, John P. Leonard, Leo I. Gordon, John Sweetenham, Baha Alkuzweny, Deborah M. Finucane, Bryan R. Leigh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

142 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences